Home>
Stocks>
Balaxi Pharmaceuticals Ltd

Balaxi Pharmaceuticals Ltd (BALAXI)

₹599.1▲0.61%

Get free price alerts. Set up your Free investment account to get Live Prices. >

Overview

Fundamentals

Q3 '23 Results

Technicals

News and Events

Balaxi Pharmaceuticals Ltd share Performance

₹593.5
₹605.1
₹599.1
0.93%
Low
Day's Volatility:1.94%
High
1.00%
₹399.95
₹686.3
₹599.1
33.24%
Low
52 Weeks Volatility:47.80%
High
14.56%

Returns %
1 Month Return	4.41 %
3 Month Return	39.1 %
1 Year Return	12.75 %

Market Stats
Previous Close	₹602.80
Open	₹601.25
Volume	2,639.00
Upper Circuit	-
Lower Circuit	-
Market Cap	₹656.92Cr

Company Information

Balaxi Ventures Limited formerly known as The Anandam Rubber Company, is a public limited company established in India since 1942. In 1989, the company sold its plantations to focus on investments and trading. The Securities and Exchange Board of India (SEBI) issued a revised Exit Policy in 2012 for derecognized/non-operational stock exchanges. Consequently, Madras Stock Exchange was derecognized by SEBI and The Anandam Rubber Company applied to list its shares with the National Stock Exchange of India (NSE) in January 2015.
In March 2017, Balaxi Overseas Pvt Ltd acquired 16,700,036 (54.94%) equity shares of the company along with its control and management. Its representatives became the new directors and the company was renamed to Balaxi Ventures. A preferential issue of 6,960,000 equity shares was approved in July 2019 and allotted in August, increasing the company’s paid-up share capital to Rs 100,000,000. Following this, Balaxi Ventures started international wholesale trading in pharmaceutical products, builders hardware, and recently launched YAP food products.

Share Price: ₹599.10 per share as on 03 May, 2024 04:01 PM
Market Capitalisation: ₹656.92Cr as of today
Revenue: ₹60.79Cr as on December 2023 (Q4 23)
Net Profit: ₹13.59Cr as on December 2023 (Q4 23)
Listing date: 30 Nov, 2015
Chairperson Name: Ashish Maheshwari

Organisation	Balaxi Pharmaceuticals Ltd
Headquarters
Industry	Trading
E-voting on shares	Click here to vote

Key events for Balaxi Pharmaceuticals Ltd

Balaxi Pharmaceuticals Approves Stock Split - 28 Feb, 2024
Balaxi Pharmaceuticals' board has approved a proposal for the sub-division/split of equity shares in the ratio of 1:5, leading to an increase in share price by nearly 8.04%. The move aims to increase liquidity, broaden the shareholder base, and make shares more affordable to small investors.

Fundamentals of Balaxi Pharmaceuticals Ltd

Insights on Balaxi Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 3 months, BALAXI stock has moved up by 39.1%
POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 60.65 Cr → 62.29 Cr (in ₹), with an average increase of 2.6% per quarter
NO EFFECT
FII Holding Unchanged
Foreign Institutions holdings remained unchanged at 18.57% of holdings in Dec 2023 quarter
NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 71.22% of holdings in Dec 2023 quarter
NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 130.4% return, outperforming this stock by 127.6%
NO EFFECT
Against Peers
In the last 1 year, Sun Pharmaceuticals Industries Ltd has given 57.6% return, outperforming this stock by 44.9%
NO EFFECT
Retail Holding Unchanged
Retail Investor holdings remained unchanged at 10.18% of holdings in Dec 2023 quarter
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 14.43 Cr → 13.59 Cr (in ₹), with an average decrease of 5.8% per quarter